Merck KGaA / Key word(s): Change of Personnel 18.09.2014 10:11 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Merck Strengthens Executive Board Merck hereby announces that today E. Merck KG has appointed Stefan Oschmann (57) to the position of Vice Chairman and Deputy CEO. Concurrently, Belén Garijo (54) has been appointed to the Executive Board to take over leadership for the Pharma business. The management changes will be effective as of January 1, 2015. Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chief Executive Officer and Chairman of the Executive Board, in his responsibilities. Both will share strategic management functions and represent the company with politicians and international organizations. As a member of the Executive Board, Garijo, currently CEO of Merck's biopharmaceutical division Merck Serono, will take on responsibility for the whole Pharma business, which in addition to Merck Serono comprises Consumer Health, Allergy and Biosimilars. 18.09.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Merck KGaA Frankfurter Str. 250 64293 Darmstadt Germany Phone: +49 (0)6151 72 - 3321 Fax: +49 (0)6151 72 - 913321 E-mail: [email protected] Internet: www.merck.de ISIN: DE0006599905 WKN: 659990 Indices: DAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart; Terminbörse EUREX; London, SIX End of Announcement DGAP News-Service ---------------------------------------------------------------------------